Federal Register / Vol. 89, No. 6 / Tuesday, January 9, 2024 / Notices 1105 

TOTAL ESTIMATED ANNUALIZED BURDEN HOURS

Form name Number of 

respondents 

Number of 

responses per 

respondent 

Total 

responses 

Average 

burden per 

response 

(in hours) 

Total burden 

hours 

Direct Financial Support Program ....................................... 619 1 619 2.7 1,671.3 

Infrastructure Program ......................................................... 219 1 219 4.8 1,051.2 

Multipurpose or Hybrid Program .......................................... 1,044 1 1,044 3.1 3,236.4 

Total .............................................................................. 1,882 ........................ 1,882 ........................ 5,958.9 

HRSA specifically requests comments 

on: (1) the necessity and utility of the 

proposed information collection for the 

proper performance of the agency’s 

functions; (2) the accuracy of the 

estimated burden; (3) ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) the 

use of automated collection techniques 

or other forms of information 

technology to minimize the information 

collection burden. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2024–00210 Filed 1–8–24; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Meeting of the Advisory Committee on 

Heritable Disorders in Newborns and 

Children 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services. 

ACTION: Notice. 

SUMMARY: In accordance with section 

1111(g) of the Public Health Service Act, 

and the Federal Advisory Committee 

Act, this notice announces that the 

Advisory Committee on Heritable 

Disorders in Newborns and Children 

(ACHDNC or Committee) has scheduled 

a public meeting. Information about the 

ACHDNC and the agenda for this 

meeting can be found on the ACHDNC 

website at https://www.hrsa.gov/ 

advisory-committees/heritabledisorders/index.html. 

DATES: Monday, January 29, 2024, from 

10 a.m. to 5 p.m. Eastern Time (ET) and 

Tuesday, January 30, 2024, from 10 a.m. 

to 3 p.m. ET. 

ADDRESSES: This meeting will be held in 

person with webcast options. While this 

meeting is open to the public, advance 

registration is required. Please visit the 

ACHDNC website for information on 

registration, https://www.hrsa.gov/ 

advisory-committees/heritabledisorders/index.html, by the deadline of 

12 p.m. ET on Friday, January 26, 2024. 

Instructions on how to access the 

meeting via webcast will be provided 

upon registration. If you are a nonUnited States citizen who would like to 

attend the January meeting in-person, 

please contact ACHDNC@hrsa.gov by 

January 11, 2024. 

FOR FURTHER INFORMATION CONTACT: Kim 

Morrison, Maternal and Child Health 

Bureau, HRSA, 5600 Fishers Lane, 

Room, Rockville, Maryland 20857; 301– 

822–4978; or ACHDNC@hrsa.gov. 

SUPPLEMENTARY INFORMATION: ACHDNC 

provides advice and recommendations 

to the Secretary of Health and Human 

Services (Secretary) on the development 

of newborn screening activities, 

technologies, policies, guidelines, and 

programs for effectively reducing 

morbidity and mortality in newborns 

and children having, or at risk for, 

heritable disorders. ACHDNC reviews 

and reports regularly on newborn and 

childhood screening practices, 

recommends improvements in the 

national newborn and childhood 

screening programs, and fulfills 

requirements stated in the authorizing 

legislation. In addition, ACHDNC’s 

recommendations regarding inclusion of 

additional conditions for screening on 

the Recommended Uniform Screening 

Panel (RUSP), following adoption by the 

Secretary, are evidence-informed 

preventive health services provided for 

in the comprehensive guidelines 

supported by HRSA pursuant to section 

2713 of the Public Health Service Act 

(42 U.S.C. 300gg–13). Under this 

provision, non-grandfathered group 

health plans and health insurance 

issuers offering non-grandfathered 

group or individual health insurance are 

required to provide insurance coverage 

without cost-sharing (a co-payment, coinsurance, or deductible) for preventive 

services for plan years (i.e., policy years) 

beginning on or after the date that is one 

year from the Secretary’s adoption of the 

condition for screening. 

During the January 29–30, 2024, 

meeting, ACHDNC will hear from 

experts in the fields of public health, 

medicine, heritable disorders, rare 

disorders, and newborn screening. 

Agenda items include the following 

topics: 

(1) A possible presentation on 

qualitative research that focuses on 

family perspectives; 

(2) Updates from Committee ad hoc 

topic groups. Potential topics include: 

the nomination process and revisions to 

the decision matrix; 

(3) An update on the evidence review 

of Duchenne muscular dystrophy 

nomination; and 

(4) Presentation of the final evidencebased review report on the Krabbe 

disease condition nomination for 

possible inclusion on the RUSP. 

Following this report presentation, the 

ACHDNC expects to vote on the second 

meeting day, on January 30, 2024, 

whether to recommend to the Secretary 

adding Krabbe disease to the RUSP 

(with potential implications under 

section 2713 of the Public Health 

Service Act, as noted above). 

The agenda for this meeting includes 

a potential vote to recommend a 

nominated condition (Krabbe disease) 

be added by the Secretary to the RUSP. 

Agenda items are subject to change as 

priorities dictate. Information about the 

ACHDNC, including a roster of members 

and past meeting summaries, is also 

available on the ACHDNC website. 

Members of the public also will have 

the opportunity to provide comments on 

any or all of the above agenda items. 

Public participants may request to 

provide general oral comments and may 

submit written statements in advance of 

the scheduled meeting. Oral comments 

will be honored in the order they are 

requested and may be limited as time 

allows. Subject to change: members of 

the public registered to submit oral 

public comments on Krabbe disease are 

tentatively scheduled to provide their 

statements on Tuesday, January 30, 

2024. Members of the public registered 

to provide oral public comments on all 

other newborn screening related topics 

are tentatively scheduled to provide 


khammond on DSKJM1Z7X2PROD with NOTICES
1106 Federal Register / Vol. 89, No. 6 / Tuesday, January 9, 2024 / Notices 

their statements on Monday, January 29, 

2024. Requests to provide a written 

statement or make oral comments to 

ACHDNC must be submitted via the 

registration website by 12 p.m. ET on 

Tuesday, January 17, 2024. Written 

comments will be shared with the 

Committee prior to the meeting so that 

they have an opportunity to consider 

them in advance of the meeting. 

Individuals who need special assistance 

or another reasonable accommodation 

should notify Kim Morrison at the 

address and phone number listed above 

at least 10 business days prior to the 

meeting. 

Since this meeting occurs in a federal 

government building, attendees must go 

through a security check to enter the 

building. Non-United States Citizen 

attendees must notify HRSA of their 

planned attendance at least 15 business 

days prior to the meeting in order to 

facilitate their entry into the building. 

All attendees are required to present 

government-issued identification prior 

to entry. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2024–00264 Filed 1–8–24; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of Closed 

Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Eye Institute 

Special Emphasis Panel; Center Core Grant 

for Vision Research (P30). 

Date: February 20, 2024. 

Time: 11:00 a.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Eye Institute, 6700B 

Rockledge Drive, Bethesda, MD 20817 

(Virtual Meeting). 

Contact Person: Brian Hoshaw, Ph.D., 

Designated Federal Official, Division of 

Extramural Research, National Eye Institute, 

National Institutes of Health, 6700 B 

Rockledge Dr., Rockville, MD 20892, 301– 

451–2020, hoshawb@mail.nih.gov. 

Name of Committee: National Eye Institute 

Special Emphasis Panel; Clinical 

Applications. 

Date: February 27, 2024. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Eye Institute, 6700 

Rockledge Drive, Bethesda, MD 20817 

(Virtual Meeting). 

Contact Person: Ashley Fortress, Ph.D., 

Designated Federal Official, Division of 

Extramural Activities, National Eye Institute, 

National Institutes of Health, 6700 B 

Rockledge Dr., Bethesda, MD 20817, (301) 

451–2020 ashley.fortress@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program No. 93.867, Vision Research, 

National Institutes of Health, HHS) 

Dated: January 4, 2024. 

Victoria E. Townsend, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–00212 Filed 1–8–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Mental Health; 

Notice of Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

Measures to Advance Quality in Mental 

Health Services. 

Date: February 6, 2024. 

Time: 12:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Serena Chu, Ph.D., 

Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, National Institutes of Health, 

Neuroscience Center, 6001 Executive Blvd. 

Bethesda, MD 20852, 301–500–5829, 

serena.chu@nih.gov. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; NonPharmacological Clinical Trials. 

Date: February 8, 2024. 

Time: 11:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Serena Chu, Ph.D., 

Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, National Institutes of Health, 

Neuroscience Center, 6001 Executive Blvd., 

Bethesda, MD 20852, 301–500–5829, 

serena.chu@nih.gov. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

BRAIN Initiative: Research on the Ethical 

Implications of Advancements in 

Neurotechnology and Brain Science (R01). 

Date: February 9, 2024. 

Time: 12:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Rebecca Steiner Garcia, 

Ph.D., Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, National Institutes of Health, 

Neuroscience Center, 6001 Executive Blvd., 

Bethesda, MD 20892–9608, 301–443–4525, 

steinerr@mail.nih.gov. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; Early 

Phase Clinical Trials: Pharma/Device and K 

Awards. 

Date: February 22, 2024. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Virtual 

Meeting). 

Contact Person: Regina Dolan-Sewell, 

Ph.D., Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, National Institutes of Health, 

Neuroscience Center, 6001 Executive Blvd., 

Bethesda, MD 20852, (240) 796–6785, 

regina.dolan-sewell@nih.gov. 

Name of Committee: National Institute of 

Mental Health Special Emphasis Panel; 

BRAIN R01. 

Date: February 28, 2024. 

Time: 11:00 a.m. to 6:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard Rockville, MD 20852, (Virtual 

Meeting). 

Contact Person: EMMA Perez-Costas, 

Ph.D., Scientific Review Officer, Division of 

Extramural Activities, National Institute of 

Mental Health, National Institutes of Health, 


khammond on DSKJM1Z7X2PROD with NOTICES